D1- and D2-receptor antagonists induce catalepsy via different efferent striatal pathways [corrected].

Article date: 1988/3/10

PubMed ID: 2966309

Journal name: Neuroscience letters (ISSN: 0304-3940)


The D1- and D2-receptor antagonists SCH 23390 and raclopride produced a dose-dependent catalepsy as studied by a vertical grid test in the male rat. The benzodiazepine antagonist Ro 15-1788 antagonized catalepsy induced by the D2-receptor antagonist raclopride while it failed to block the action of SCH 23390. The antimuscarinic drug scopolamine reduced and the gamma-aminobutyric acid (GABA) agonist muscimol enhanced catalepsy induced by both SCH 23390 and raclopride. The results suggest that D2-antagonist-induced catalepsy is mainly mediated via activation of the strio-pallidal GABA pathways whereas D1-receptor antagonist induced catalepsy is mainly mediated via increased activity in the nigrothalamic GABA pathways.

Author List: Ogren S O, Fuxe K

Publication Types: Journal Article; Research Support, Non-U.S. Gov't

Substances mentioned in the article: Benzazepines; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Salicylamides; Muscimol; Flumazenil; Raclopride; Scopolamine Hydrobromide; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine;

Mesh terms: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines/administration & dosage; Catalepsy; Corpus Striatum/drug effects; Dose-Response Relationship, Drug; Flumazenil/administration & dosage; Injections, Intraperitoneal; Male; Muscimol/administration & dosage; Raclopride; Rats; Rats, Inbred Strains; Receptors, Dopamine/drug effects; Receptors, Dopamine D1; Receptors, Dopamine D2; Salicylamides/administration & dosage; Scopolamine Hydrobromide/administration & dosage;

2966309.txt · Last modified: 2018/11/20 14:26 (external edit)